Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years: Results from 2 randomized controlled trials

Immunogenicity and safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine were evaluated in healthy Chinese females aged 9–45 years in 2 phase IIIB, randomized, controlled trials. Girls aged 9–17 years (ClinicalTrials.gov, NCT00996125) received vaccine (n = 374) or control (n = 376)...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Fengcai, Li, Juan, Hu, Yuemei, Zhang, Xiang, Yang, Xiaoping, Zhao, Hui, Wang, Junzhi, Yang, Jianguo, Xia, Guodong, Dai, Qinyong, Tang, Haiwen, V Suryakiran, Pemmaraju, Datta, Sanjoy K, Descamps, Dominique, Bi, Dan, Struyf, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186032/
https://www.ncbi.nlm.nih.gov/pubmed/25424785
http://dx.doi.org/10.4161/hv.28702

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186032/
https://www.ncbi.nlm.nih.gov/pubmed/25424785
http://dx.doi.org/10.4161/hv.28702

Ejemplares similares